Accentia Biopharmaceuticals acquires exclusive license

Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) announced today that it has entered into an exclusive license with Collegium Pharmaceuticals, Inc. (Collegium) to market in the U.S., a branded intranasal steroid intended for the symptoms of seasonal and perennial allergic rhinitis . This product will be marketed by Accentia's specialty pharmaceutical division, TEAMM Pharmaceuticals. This license will expand Accentia's pipeline of innovative products for respiratory diseases and enable Accentia to enter the large intranasal steroid market. Collegium plans to file a Supplemental New Drug Application (sNDA) in 2006 for this patent-pending aqueous nasal spray formulation.

"The intranasal steroid market in the US represents approximately $2.7 billion dollars in annual sales. The primary competition for this market has been prescription non-sedating oral antihistamine products which have annual sales in excess of $4 billion dollars in the US. We anticipate that over the next several years many of the non-sedating antihistamines will migrate to the over-the-counter (OTC) marketplace. This anticipated shift in the market may benefit growth in the intranasal steroid prescription market." said Michael Heffernan, President of Collegium. "We believe that our new product will have a favorable profile within the nasal steroid market".

"This is an excellent addition to our focus on innovative products to treat respiratory diseases. Our respiratory product portfolio includes the recently announced launch of our CRSFungal ProfileTM, a unique non-invasive test for confirmation of the diagnosis of chronic sinusitis and differentiation of it from allergic rhinitis," said Martin Baum, President and COO of specialty pharmaceuticals at Accentia. "In early 2006, we expect to launch MDTurboTM , a unique, patented delivery device for metered dose inhalers used to treat asthma and chronic obstructive pulmonary disease. In addition, our pipe

Contact: Sherran Brewer

Page: 1 2

Related biology news :

1. FDA grants Accentia Biopharmaceuticals...
2. Accentia Biopharmaceuticals announces option agreement with Mayo
3. AutovaxID-C introduced by Accentia Biopharmaceuticals
4. Accentia Biopharmaceuticals, Inc. launches CRSFungal Profile
5. Macrochem acquires option to license pexiganan
6. Biogen Idec acquires Brandeis spin-out
7. Wiley acquires publications from Carpe Diem Communications
8. Ossur hf. acquires the Gibaud Group in France
9. Springer acquires BioTribune Magazine and Biotribune.com
10. Stevens Davidson Laboratory acquires new research vessel
11. Ossur acquires US orthotics company Royce Medical

Post Your Comments:

(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: